PharmaCyte Biotech Addresses Development of Targeted Cannabinoid Chemotherapy

PharmaCyte Biotech, Inc. (OTCQB:PMCB) announced today that Scientific Advisory Board member Mark L. Rabe, MD, was a featured speaker at a Physicians Roundtable that took place in San Diego this past weekend. The Physicians Roundtable was designed to educate local physicians and health care providers on the topic: “The Endocannabinoid System: Leveraging the Largest Receptor System in the Human Body.”
According to the news:

Dr. Rabe’s presentation, “The Evolution of Medical Cannabis,” traced the history of Cannabis from ancient times to the present day, citing numerous references from the proliferation of medical literature that document the anti-cancer, pain-relieving, anti-inflammatory and neuroprotective effects of the “phyto”-cannabinoid molecules contained in the Cannabis plant.

Dr. Rabe commented:

In order to provide better care to their patients, it is very heartening to see health care professionals dedicate precious time on a Saturday morning to become more educated in the recommendation of an herbal medicine that a significant – and growing – number of patients report works better, with far fewer side effects, than the pharmaceutical alternatives. The work being conducted at UNC to utilize Cell-in-a-Box^® live cell encapsulation in combination with a unique bioengineered cell line to activate cannabinoid prodrugs in a targeted fashion to treat cancer, and potentially other diseases, exemplifies where things are headed in the future.

Click here to view the full release.